Ambrilia lays off CEO, CFO

Ambrilia Biopharma is making more cuts to its budget. The Canadian company announced yesterday that it has laid off CEO Philippe Calais, CFO Monique Letourneau, and two other senior managers. Richard La Rue has been appointed Interim CEO. Ambrilia has sold off an early-stage cancer program and halted a Phase III trial as it looks for additional funding to support its operations. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.